Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in cancer therapy
Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber · 2026
Read Agent-based modeling demonstrates how target-independent processes supplement killing by antibody-drug conjugates in cancer therapy by Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13274927.txt.
Description
Melissa C. Calopiz, Jennifer J. Linderman, and Greg M. Thurber modeled how antibody-drug conjugates kill tumors beyond their target in a 2026 simulation study. One leading drug works even when its target, HER2, is barely present on cancer cells, which target binding alone cannot explain. Lab doses differ too much from clinic doses for simple scaling.
Their agent based model, SimADC, scales results from mice to humans and tests each proposed side route. Immune T cells could add major killing, especially if the drug wakes them further. Drug swallowed by tumor macrophages and then released nearby gave strong effects, free drug in blood gave weak effects, and outside linker cutting gave moderate effects. Moderate to high target levels still beat the side routes overall.
Catalog record
| CREATOR | Melissa C. Calopiz, Jennifer J. Linderman, Greg M. Thurber |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 86 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |